This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Pfizer’s respiratory syncytial virus vaccine, Abrysvo

Ticker(s): PFE

Who's the expert?

An infectiologist with experience in treating RSV.

Interview Questions

Can you tell us more about respiratory syncytial virus and how serious it is?

Added By: slingshot_insights

What are the potential risks associated with the Abrysvo vaccine?

Added By: slingshot_insights

What is the expected market size for the Abrysvo vaccine?

Added By: slingshot_insights

What is the competition landscape for respiratory syncytial virus vaccines?

Added By: slingshot_insights

What are some of your high level thoughts in advance of the May 2023 Abrysvo vaccine PDUFA, and it further reaching the market?

Added By: slingshot_insights

Do you think the company's track record of successful vaccine launches will add any weight?

Added By: slingshot_insights

What is the potential impact of the Abrysvo vaccine on the general RSV landsacape?

Added By: slingshot_insights

Do you see any potential regulatory or legal hurdles related to the Abrysvo vaccine?

Added By: slingshot_insights

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.